BlackRock Investment Management’s Blueprint Medicines BPMC Stock Holding History

BlackRock Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.16M	Sell	77,162 -206	-0.3%	-$6.21K	﹤0.01%	2172
2016 Q3	$2.3M	Buy	77,368 +332	+0.4%	+$8.25K	﹤0.01%	2046
2016 Q2	$1.56M	Buy	77,036 +43,834	+132%	+$797K	﹤0.01%	2316
2016 Q1	$599K	Buy	33,202 +494	+2%	+$8.57K	﹤0.01%	2813
2015 Q4	$862K	Buy	32,708 +183	+0.6%	+$4.12K	﹤0.01%	2709
2015 Q3	$694K	Sell	32,525 -723	-2%	-$20K	﹤0.01%	2865
2015 Q2	$881K	Buy	+33,248	New	+$950K	﹤0.01%	2865

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Investment Management's BPMC Position: Q4 2016 in Review

BlackRock Investment Management reduced its Blueprint Medicines (BPMC) stake by 0.27% in Q4 2016, selling an estimated $6.21K and leaving 77,162 shares worth $2.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

BlackRock Investment Management first reported a position in BPMC in Q2 2015 and has held it in 7 quarters since. The position peaked at $2.3M in Q3 2016. 103 funds tracked by Wall St. Rank hold BPMC as of Q4 2016.

BlackRock Investment Management held 77,162 shares of Blueprint Medicines worth $2.16M as of Q4 2016.
BlackRock Investment Management sold 206 Blueprint Medicines shares in Q4 2016, an estimated $6.21K.
Blueprint Medicines made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2172 holding.
BlackRock Investment Management first reported a position in Blueprint Medicines in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Blueprint Medicines position peaked at $2.3M in Q3 2016.
103 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.